Cholesterol and its association with muscle weakness in critical illness

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1364-8535

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Cholesterol and its association with muscle weakness in critical illness ; volume:25 ; number:1 ; day:17 ; month:8 ; year:2021 ; pages:1-2 ; date:12.2021
Critical care ; 25, Heft 1 (17.8.2021), 1-2, 12.2021

Creator: Hofmaenner, Daniel A.
Kleyman, Anna
Singer, Mervyn

Contributor: SpringerLink (Online service)

DOI: 10.1186/s13054-021-03722-2

URN: urn:nbn:de:101:1-2021110521000128267901

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:37 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Hofmaenner, Daniel A.
Kleyman, Anna
Singer, Mervyn
SpringerLink (Online service)

Other Objects (12)

Altered cholesterol homeostasis in critical illness-induced muscle weakness: effect of exogenous 3-hydroxybutyrate

Impaired Ca2+ release contributes to muscle weakness in a rat model of critical illness myopathy

Mitochondrial function in skeletal muscle of patients with protracted critical illness and ICU-acquired weakness

Glucocorticoid treatment increases cholesterol availability during critical illness: effect on adrenal and muscle function

Acute Nontraumatic Muscle Weakness

Critical Illness Weakness, Polyneuropathy and Myopathy: Diagnosis, treatment, and long-term outcomes

Development of muscle weakness in a mouse model of critical illness: does fibroblast growth factor 21 play a role?

Publisher Correction to: Critical Illness Weakness, Polyneuropathy and Myopathy: Diagnosis, treatment, and long‑term outcomes

Respiratory muscle weakness in facioscapulohumeral muscular dystrophy

Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness

Expanding the scope of prehabilitation: reducing critical illness weakness across elective surgical patients scheduled for postoperative ICU care

Understanding and combating age-related muscle weakness: MYOAGE challenge

Altered cholesterol homeostasis in critical illness-induced muscle weakness: effect of exogenous 3-hydroxybutyrate

Impaired Ca2+ release contributes to muscle weakness in a rat model of critical illness myopathy

Mitochondrial function in skeletal muscle of patients with protracted critical illness and ICU-acquired weakness

Glucocorticoid treatment increases cholesterol availability during critical illness: effect on adrenal and muscle function

Acute Nontraumatic Muscle Weakness

Critical Illness Weakness, Polyneuropathy and Myopathy: Diagnosis, treatment, and long-term outcomes

Development of muscle weakness in a mouse model of critical illness: does fibroblast growth factor 21 play a role?

Publisher Correction to: Critical Illness Weakness, Polyneuropathy and Myopathy: Diagnosis, treatment, and long‑term outcomes

Respiratory muscle weakness in facioscapulohumeral muscular dystrophy

Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness

Expanding the scope of prehabilitation: reducing critical illness weakness across elective surgical patients scheduled for postoperative ICU care

Understanding and combating age-related muscle weakness: MYOAGE challenge

Altered cholesterol homeostasis in critical illness-induced muscle weakness: effect of exogenous 3-hydroxybutyrate

Impaired Ca2+ release contributes to muscle weakness in a rat model of critical illness myopathy

Mitochondrial function in skeletal muscle of patients with protracted critical illness and ICU-acquired weakness

Glucocorticoid treatment increases cholesterol availability during critical illness: effect on adrenal and muscle function

Acute Nontraumatic Muscle Weakness

Critical Illness Weakness, Polyneuropathy and Myopathy: Diagnosis, treatment, and long-term outcomes

Development of muscle weakness in a mouse model of critical illness: does fibroblast growth factor 21 play a role?

Publisher Correction to: Critical Illness Weakness, Polyneuropathy and Myopathy: Diagnosis, treatment, and long‑term outcomes

Respiratory muscle weakness in facioscapulohumeral muscular dystrophy

Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness

Expanding the scope of prehabilitation: reducing critical illness weakness across elective surgical patients scheduled for postoperative ICU care

Understanding and combating age-related muscle weakness: MYOAGE challenge

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Cholesterol and its association with muscle weakness in critical illness

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Altered cholesterol homeostasis in critical illness-induced muscle weakness: effect of exogenous 3-hydroxybutyrate

Impaired Ca2+ release contributes to muscle weakness in a rat model of critical illness myopathy

Mitochondrial function in skeletal muscle of patients with protracted critical illness and ICU-acquired weakness

Glucocorticoid treatment increases cholesterol availability during critical illness: effect on adrenal and muscle function

Acute Nontraumatic Muscle Weakness

Critical Illness Weakness, Polyneuropathy and Myopathy: Diagnosis, treatment, and long-term outcomes

Development of muscle weakness in a mouse model of critical illness: does fibroblast growth factor 21 play a role?

Publisher Correction to: Critical Illness Weakness, Polyneuropathy and Myopathy: Diagnosis, treatment, and long‑term outcomes

Respiratory muscle weakness in facioscapulohumeral muscular dystrophy

Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness

Expanding the scope of prehabilitation: reducing critical illness weakness across elective surgical patients scheduled for postoperative ICU care

Understanding and combating age-related muscle weakness: MYOAGE challenge

Altered cholesterol homeostasis in critical illness-induced muscle weakness: effect of exogenous 3-hydroxybutyrate

Impaired Ca2+ release contributes to muscle weakness in a rat model of critical illness myopathy

Mitochondrial function in skeletal muscle of patients with protracted critical illness and ICU-acquired weakness

Glucocorticoid treatment increases cholesterol availability during critical illness: effect on adrenal and muscle function

Acute Nontraumatic Muscle Weakness

Critical Illness Weakness, Polyneuropathy and Myopathy: Diagnosis, treatment, and long-term outcomes

Development of muscle weakness in a mouse model of critical illness: does fibroblast growth factor 21 play a role?

Publisher Correction to: Critical Illness Weakness, Polyneuropathy and Myopathy: Diagnosis, treatment, and long‑term outcomes

Respiratory muscle weakness in facioscapulohumeral muscular dystrophy

Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness

Expanding the scope of prehabilitation: reducing critical illness weakness across elective surgical patients scheduled for postoperative ICU care

Understanding and combating age-related muscle weakness: MYOAGE challenge

Altered cholesterol homeostasis in critical illness-induced muscle weakness: effect of exogenous 3-hydroxybutyrate

Impaired Ca2+ release contributes to muscle weakness in a rat model of critical illness myopathy

Mitochondrial function in skeletal muscle of patients with protracted critical illness and ICU-acquired weakness

Glucocorticoid treatment increases cholesterol availability during critical illness: effect on adrenal and muscle function

Acute Nontraumatic Muscle Weakness

Critical Illness Weakness, Polyneuropathy and Myopathy: Diagnosis, treatment, and long-term outcomes

Development of muscle weakness in a mouse model of critical illness: does fibroblast growth factor 21 play a role?

Publisher Correction to: Critical Illness Weakness, Polyneuropathy and Myopathy: Diagnosis, treatment, and long‑term outcomes

Respiratory muscle weakness in facioscapulohumeral muscular dystrophy

Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness

Expanding the scope of prehabilitation: reducing critical illness weakness across elective surgical patients scheduled for postoperative ICU care

Understanding and combating age-related muscle weakness: MYOAGE challenge

Related objects

Reset password